A double-blind, placebo-controlled, dose ranging phase II study to determine the lowest effective dose of ATB-346 for osteoarthritis
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs ATB 346 (Primary)
- Indications Pain
- Focus Therapeutic Use
- 18 Apr 2017 According to an Antibe Therapeutics media release, this trial is expected to be completed by the end of Q2 2018.
- 29 Nov 2016 According to an Antibe Therapeutics media release, this trial is expected to initiate in 2017.
- 09 Nov 2016 New trial record